Home › NDC Lookup › RxCUI directory › RxCUI 752869

Mirtazapine 15 MG Disintegrating Oral Tablet [Remeron] — RxCUI 752869

RxNorm drug concept · Semantic branded drug
RxCUI 752869 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI752869
Official nameMirtazapine 15 MG Disintegrating Oral Tablet [Remeron]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRemeron 15 MG Disintegrating Oral Tablet; Remeron SolTab 15 MG Disintegrating Oral Tablet
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)12 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mirtazapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mirtazapine is prescribed to treat major depressive disorder (MDD) in adults. That's a medical condition involving a persistently low mood, loss of interest in daily activities, ch...
  • Mirtazapine causes significant drowsiness — it's one of its most common effects. Taking it in the evening before bed means that sleepiness works in your favor rather than interferi...
  • Why is it recommended to take mirtazapine in the evening?
  • Yes, weight gain and increased appetite are well-documented side effects of mirtazapine. In clinical trials, about 12% of patients on mirtazapine gained weight, compared to 2% on p...
📖 Read our full Mirtazapine guide →

🕸️ Concept Web — How Mirtazapine 15 MG Disintegrating Oral Tablet [Re... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mirtazapine 15 MG Disintegrating Oral Tablet [Remeron] RxCUI 752869

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mirtazapine 15996
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Remeron 134774
  3. Dose forms 12

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mirtazapine Disintegrating Oral Tablet 378442
    • Mirtazapine Disintegrating Oral Product 1295464
    • Mirtazapine Oral Product 1165364
    • Mirtazapine Pill 1165365
    • Mirtazapine Disintegrating Oral Tablet [Remeron] 752868
    • Remeron Disintegrating Oral Product 1296602
    • Remeron Oral Product 1180723
    • Remeron Pill 1180724
    • +4 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mirtazapine 15 MG Disintegrating Oral Tablet SCD · 283406
  • Mirtazapine 15 MG SCDC · 343091
  • Mirtazapine Disintegrating Oral Tablet SCDF · 378442
  • Mirtazapine Disintegrating Oral Product SCDG · 1295464
  • Mirtazapine Oral Product SCDG · 1165364
  • Mirtazapine Pill SCDG · 1165365

Brand-Name Concepts

  • Mirtazapine 15 MG [Remeron] SBDC · 571764
  • Mirtazapine Disintegrating Oral Tablet [Remeron] SBDF · 752868
  • Remeron Disintegrating Oral Product SBDG · 1296602
  • Remeron Oral Product SBDG · 1180723
  • Remeron Pill SBDG · 1180724
  • Remeron BN · 134774

📦 FDA Products & Package NDCs

5 products · 5 package NDCs
5 package NDCs map to RxCUI 752869 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
78206-0156-01 5 BLISTER PACK in 1 BOX (78206-156-01) / 6 TABLET, ORALLY D... REMERONSOLTAB Organon LLC 2021-06-01
78206-0158-01 5 BLISTER PACK in 1 BOX (78206-158-01) / 6 TABLET, ORALLY D... REMERONSOLTAB Organon LLC 2021-06-01
78206-0159-01 5 BLISTER PACK in 1 BOX (78206-159-01) / 6 TABLET, ORALLY D... REMERONSOLTAB Organon LLC 2021-06-01
78206-0160-01 30 TABLET, FILM COATED in 1 BOTTLE (78206-160-01) REMERON Organon LLC 2021-06-01
78206-0161-01 30 TABLET, FILM COATED in 1 BOTTLE (78206-161-01) REMERON Organon LLC 2021-06-01
Observed labelers: Organon LLC (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.